- |||||||||| cyclophosphamide / Generic mfg., doxorubicin hydrochloride / Generic mfg.
Trial completion date, Trial primary completion date: AKY15-HK-301_NEPA Study (clinicaltrials.gov) - Sep 15, 2022 P2, N=60, Recruiting, Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
- |||||||||| prednisone / Generic mfg., methylprednisolone sodium succinate / Generic mfg.
Trial completion date, Trial primary completion date: Effect of Corticosteroids on Inflammation at the Edge of Acute Multiple Sclerosis Plaques (clinicaltrials.gov) - Sep 15, 2022 P2, N=30, Recruiting, Trial completion date: Dec 2022 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024 Trial completion date: Apr 2023 --> Dec 2024 | Trial primary completion date: Apr 2023 --> Dec 2024
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg.
Enrollment open, Trial completion date, Trial primary completion date, Combination therapy, IO biomarker: FIL_DALYA: Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients. (clinicaltrials.gov) - Sep 15, 2022 P2, N=28, Recruiting, Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Jun 2022 --> Feb 2024
- |||||||||| Veramyst (fluticasone furoate nasal spray) / GSK
Journal: A 32-Year-Old Man with Persistent Olfactory Dysfunction Following COVID-19 Whose Recovery Was Evaluated by Retronasal Olfactory Testing. (Pubmed Central) - Sep 14, 2022 After 3 months of olfactory training and therapy with steroidal nasal drops (Fluticasone Furoate, 27.5 µg/day) and oral vitamins (Mecobalamin, 1500 µg/day), the patient's orthonasal test olfactory threshold score improved to 0.6 points (normal), and his olfactory identification result improved to 1.2 points (mild decrease)...At this time, the patient did not report any improvement in his symptoms. CONCLUSIONS This report has shown that in cases of persistent anosmia following COVID-19, retronasal olfactory testing can be used to evaluate recovery of the sense of smell.
- |||||||||| dexamethasone / Generic mfg., trimethoprim/sulfamethoxazole / Generic mfg.
Journal: Pulmonary Nocardiosis as an Opportunistic Infection in COVID-19. (Pubmed Central) - Sep 14, 2022 The efficacy of prednisone and dexamethasone is similar. Nocardia are responsible for opportunistic pulmonary infections after steroid treatment.We describe a case of pulmonary nocardiosis following critical COVID-19 pneumonia.Physicians should be aware of the possibility of secondary nocardiosis in COVID-19 inpatients.
- |||||||||| methylprednisolone sodium succinate / Generic mfg., azathioprine / Generic mfg.
Journal: Aseptic meningitis in Fabry disease due to a novel GLA variant: an expanded phenotype? (Pubmed Central) - Sep 14, 2022 Understanding the mechanisms underlying meningitis and its association with cerebrovascular events may lead to a new paradigm of treatment for stroke in these patients. Further prospective studies with CSF collection in patients with FD and recurrent headache could help to elucidate this question.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Dereplication of Siparuna brasiliensis extract with in vivo anti-inflammatory activity. (Pubmed Central) - Sep 14, 2022 From their charge-to-mass ratios (m/z) and elemental composition obtained through Ultrahigh-resolution mass spectrometry analysis by ESI(-)-Orbitrap MS and chromatographic profile by RP-HPLC-PDA, it was possible to annotate polyphenols with anti-inflammatory properties classified as flavonoids and organic acids. The administration of the extract significantly inhibited carrageenan-induced paw edema and showed effects similar to those of drug dexamethasone without affecting cell viability.
- |||||||||| oxaliplatin / Generic mfg.
Journal: Dose dependent slurred speech and laryngopharyngeal dysesthesia due to oxaliplatin. (Pubmed Central) - Sep 14, 2022 The administration of the extract significantly inhibited carrageenan-induced paw edema and showed effects similar to those of drug dexamethasone without affecting cell viability. Occurrence of laryngopharyngeal dysesthesia due to oxaliplatin does not warrant drug withdrawal, dose titration can be helpful, thereby preventing the drug withdrawal for the patient management.
- |||||||||| dexamethasone / Generic mfg.
Journal, HEOR: Comparative Effectiveness of Dexamethasone in Hospitalized COVID-19 Patients in the United States. (Pubmed Central) - Sep 14, 2022 Hospitalized adult patients with COVID-19 who required supplemental oxygen and received dexamethasone did not have a survival benefit versus similar patients not receiving dexamethasone. The dexamethasone group was not associated with favorable responses for outcomes such as progression to death or mechanical ventilation and time to in-hospital death.
- |||||||||| dexamethasone / Generic mfg., cytarabine / Generic mfg.
Journal: Risk factors for early death or euthanasia within 100 days of diagnosis in dogs with meningoencephalitis of unknown origin. (Pubmed Central) - Sep 14, 2022 No other clinical, MRI feature, or treatment was found to have a significant influence on survival. Obtundation at presentation was found to increase risk of early euthanasia in dogs with MUO, while the addition of an IV infusion of cytarabine to immune-suppressive corticosteroid therapy (prednisolone and / or dexamethasone) at initial treatment did not improve the odds of survival at 7, 30, or 100 days after diagnosis.
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
Journal: A novel logical model of COVID-19 intracellular infection to support therapies development. (Pubmed Central) - Sep 14, 2022 Specifically, the combination of the anti-inflammatory Baricitinib and the anti-viral Remdesivir showed significant benefits while a stronger efficacy emerged from the triple combination of Baricitinib, Remdesivir, and the corticosteroid Dexamethasone. Together with a sensitivity analysis, we performed an analysis of the mechanisms of the drugs to reveal their impact on molecular pathways.
- |||||||||| dexamethasone / Generic mfg.
Preclinical, Journal: Antiosteoporosis and bone protective effect of dieckol against glucocorticoid-induced osteoporosis in rats. (Pubmed Central) - Sep 14, 2022 Sprague-Dawley (SD) rats were used for the current study and dexamethasone (2.5 mg/kg) induced osteoporosis in the rats that received the dieckol (test) and alendronate (standard) for 20 weeks...Dieckol also suppressed the level of receptor activator of nuclear factor κB ligand (RANKL) and boosted the level of osteoprotegerin (OPG). Taken together, our data suggest that dieckol demonstrated the anti-osteoporosis effect against GC-induced osteoporosis in rats.
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Review, Journal: Smoldering multiple myeloma current treatment algorithms. (Pubmed Central) - Sep 14, 2022 Patients with newly diagnosed high risk SMM should be offered therapy with lenalidomide or lenalidomide plus dexamethasone (Rd) for 2 years, or enrollment in clinical trials. Patients with low risk SMM should be observed without therapy every 3-4 months.
- |||||||||| dexamethasone / Generic mfg.
Journal: Re-evaluation of the low-dose dexamethasone suppression test in dogs. (Pubmed Central) - Sep 14, 2022 Thus, DLK1 might be a promising candidate to treat sarcopenia, characterized by muscle atrophy and degeneration. The optimal cut-point of more than 36 nmol/L proposed by this study is similar to the currently accepted 8-hour cortisol concentration cut-point for diagnosing hypercortisolism when using a solid-phase, competitive chemiluminescent enzyme immunoassay.
- |||||||||| budesonide/salbutamol (PT027) / AstraZeneca, Avillion
Journal: Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma. (Pubmed Central) - Sep 14, 2022 The optimal cut-point of more than 36 nmol/L proposed by this study is similar to the currently accepted 8-hour cortisol concentration cut-point for diagnosing hypercortisolism when using a solid-phase, competitive chemiluminescent enzyme immunoassay. No abstract available
- |||||||||| dexamethasone / Generic mfg.
Trial completion date: A Novel Analgesia Technique for ACL Reconstruction (clinicaltrials.gov) - Sep 14, 2022 P4, N=78, Active, not recruiting, Trial completion date: Aug 2024 --> Aug 2027 | Trial primary completion date: Aug 2022 --> Jul 2025 Trial completion date: Jul 2022 --> Jun 2024
- |||||||||| Caprelsa (vandetanib) / Sanofi
Preclinical, Journal, Cytokine storm: Vandetanib Blocks the Cytokine Storm in SARS-CoV-2-Infected Mice. (Pubmed Central) - Sep 14, 2022 Vandetanib additionally rescued the decreased IFN-1β caused by SARS-CoV-2 infection in mice to levels similar to that in uninfected animals. Our results indicate that the FDA-approved anticancer drug vandetanib is worthy of further assessment as a potential therapeutic candidate to block the COVID-19 cytokine storm.
|